US EditionPublished • loading... • Updated
Roche CEO points to higher future drug prices in Switzerland after US deal
Roche CEO Thomas Schinecker warns U.S. drug price deals could increase costs for new medicines in Switzerland, which accounts for 10% of its GDP, affecting research investment.
- On Dec 20, Roche Chief Executive Thomas Schinecker warned deals between pharmaceutical companies and Washington will likely push up new drug costs in Switzerland and urged higher payments to align prices with Washington.
- The White House's pressure prompted voluntary deals after U.S. President Donald Trump sent a summer letter to 17 major companies, with Genentech among 14 firms signing on to cut U.S. drug prices.
- Most Favoured Nation pricing commits companies like Genentech to match the lowest price in wealthy countries including Switzerland, while Schinecker said existing medicines stay stable initially and future launches will follow this system.
- Negotiators in Bern face pressure as Schinecker warned resistance to raising Swiss drug prices could cause knock-on effects, while Swiss politicians voice concern despite price cuts for the U.S. Medicaid program.
- Given Swiss GDP per capita exceeds the United States, Schinecker said prices will rise gradually with each new launch over the coming years and cautioned that `Unfortunately, this would likely lead to further delays in introducing new medicines.
Insights by Ground AI
17 Articles
17 Articles
While the US administration announced on Friday an agreement with nine new laboratories to reduce drug prices, Thomas Schinecker believes that Switzerland is the country that has "the most to win and the most to lose" in the new equation.
·Paris, France
Read Full Article
Roche CEO points to higher future drug prices in Switzerland after US deal
Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up the cost of new drugs in Switzerland, the CEO of Swiss pharma giant Roche was quoted as saying on Saturday.
·United Kingdom
Read Full Article
The agreement with Novartis and Roche will increase pressure on drug prices in Switzerland, politicians believe.
·Zürich, Switzerland
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left3Leaning Right1Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 33%
C 56%
11%
Factuality
To view factuality data please Upgrade to Premium
